Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NY7A
|
||||
| Former ID |
DNC001255
|
||||
| Drug Name |
S-19528
|
||||
| Indication | Eating disorders reduction in food intake [ICD9: 307.5; ICD10:F50] | Investigative | [1] | ||
| Company |
Servier
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Neuropeptide Y receptor type 1 | Target Info | Antagonist | [1] | |
| Neuropeptide Y receptor 5 | Target Info | Antagonist | [1] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | |||||
| Endothelin Pathways | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.